Why Northwest Biotheraputics, Inc. Shares Were Flying High Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Northwest Biotheraputics, finished the trading day with a 12% gain after the company reported excellent early results in its preliminary trials for its DCVax-Direct dendritic cell-based cancer treatment.
So what: Northwest's ongoing clinical trials of DCVax have been targeting patients with inoperable solid tumors. Of the 36 patients in the trial, 19 have completed at least half of the six DCVax treatments (none have made it all the way through the eight-month six-treatment trial period), and of these 19, 11 are showing positive responses. Eight of the 11 patients show signs of tumor necrosis (cell death) and disease stabilization, with biopsies showing "substantial to extensive" tumor necrosis and substantial accumulations of immune cells infiltrating the tumors. Six of those eight patients also showed signs of tumor shrinkage or stabilization, and while the other two patients showed some tumor growth, these enlarged tumors were largely full of dead cells.
The remaining three of the 11 positive-response patients only show signs of stabilization thus far. The remaining eight patients to complete more than half of the treatments are not yet showing any improvement, apparently.
Now what: It's too early to conclude that DCVax-Direct is an unqualified success, but this is certainly very good news for Northwest shareholders, who'd already enjoyed a double this year before shares pulled back in the spring. DCVax is also in other trials under other formulations, as its phase 3 trial for treating brain cancer is currently under way. However, that trial has come under fire in recent months for weak methodology, and the DCVax-Direct trial's small patient sample size should also keep investors from speculating too much on the drug's wider effectiveness. Treat this report with cautious optimism, but make sure you dig deeper into the data before diving in.
Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
The article Why Northwest Biotheraputics, Inc. Shares Were Flying High Today originally appeared on Fool.com.Alex Planes and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.